VERA Stock Forecast: Vera Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$25
−4.93% on the day

The 14 Wall Street analysts covering Vera Therapeutics, Inc. hold a median 12-month price target of $75 — +194.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 37 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.8B
Ticker Nerd rank
37/ 100
Median analyst target
$75
Analysts covering
14
Revenue$0.0
Operating income−$112.5M
Net income−$109.5M
Free cash flow−$100.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.5%
1M
−15.4%
YTD
−49.8%
1Y
−8.8%
From 52W high
−54.3%
From 52W low
0.0%
$25
$56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Vera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
37/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
82
Volatility
58
Value
53
Momentum
50
Issuance
41
Accruals
37
Quality
27
Growth
20

Revisions (82): Analysts have, on balance, been raising their forecasts.

Growth (20): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VERA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VERA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26VERAHigh $100Median $75Low $29

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
12
Buy
2
Hold
0
Sell
$29
Low
$75
Median
$100
High

The green dot is the last close — the median target sits +194.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
6 Nov 2026GuggenheimMaintainsBuy$76 → $66
6 Nov 2026HC Wainwright & Co.MaintainsBuy$90 → $75
6 Nov 2026WedbushMaintainsNeutral$34 → $29
12 Oct 2026Leerink PartnersInitiatesMarket Perform$34
8 Sept 2026JP MorganMaintainsOverweight$76 → $83
17 Aug 2026WedbushReiteratesNeutral$34
12 Aug 2026HC Wainwright & Co.MaintainsBuy$125 → $90
11 Aug 2026WedbushMaintainsNeutral$43 → $34
8 July 2026GuggenheimMaintainsBuy$56 → $76
8 July 2026HC Wainwright & Co.MaintainsBuy$110 → $125
8 July 2026TD CowenMaintainsBuy$73 → $78
8 July 2026WedbushMaintainsNeutral$35 → $43
7 July 2026B of A SecuritiesMaintainsBuy$65 → $70
15 May 2026Evercore ISI GroupMaintainsOutperform—
11 Mar 2026Wolfe ResearchUpgradeOutperform—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
19 Dec 2025B of A SecuritiesMaintainsBuy—
19 Dec 2025Goldman SachsMaintainsBuy—
19 Dec 2025JP MorganMaintainsOverweight—
11 Dec 2025WedbushMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VERA.

Market Radar

This page is one stock. Monday covers all of them.

VERA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VERA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Vera Therapeutics, Inc. returned −8.8% against +6.9% for the S&P 500, dividends included.

VERA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26VERAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VERA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
179.0×

Cheaper than 2% of US stocks

Price / book
5.5×

Cheaper than 16% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−113.5%

Higher than 12% of US stocks

Return on assets
−54.4%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vera Therapeutics, Inc. has a market value of $1.8B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$401.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$339.2M.

  • Shares outstanding: 72.0M.

  • Vera Therapeutics, Inc. employs 362 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

VERA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VERAVera Therapeutics, Inc.$1.8B37
REPLReplimune Group, Inc.$1.8B63
BHVNBiohaven Ltd.$1.8B53
FTREFortrea Holdings, Inc.$1.8B92
STOKStoke Therapeutics, Inc.$1.8B43
MRVIMaravai Lifesciences Holdings, Inc.$1.8B94
TRAXFirst Tracks Biotherapeutics, Inc.$1.7B4

Take a look at VERA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Vera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VERA

What is the VERA stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Vera Therapeutics, Inc. have a median 12-month price target of $75, with estimates ranging from $29 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VERA stock a buy right now?

Of the 14 analysts covering Vera Therapeutics, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vera Therapeutics, Inc. 37 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VERA?

As at 21 Nov 2026, Vera Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (82 of 100).

Will VERA stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +194.9% from the last close, and Ticker Nerd's factor model ranks Vera Therapeutics, Inc. 37 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VERA stock forecast for 2030?

No analyst covering Vera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VERA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $29 to $100 over the next 12 months.

How has VERA stock performed over the past year?

Vera Therapeutics, Inc. returned -8.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vera Therapeutics, Inc. do?

Vera Therapeutics, Inc. Class A Common Stock represents ownership in Vera Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases. The company’s current pipeline is centered on atacicept, a subcutaneous therapy being evaluated for IgA nephropathy and other autoimmune kidney diseases, alongside additional programs such as MAU868 for BK viremia infections and VT-109 for B cell-mediated autoimmune diseases.

Company

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc. Class A Common Stock represents ownership in Vera Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases. The company’s current pipeline is centered on atacicept, a subcutaneous therapy being evaluated for IgA nephropathy and other autoimmune kidney diseases, alongside additional programs such as MAU868 for BK viremia infections and VT-109 for B cell-mediated autoimmune diseases. Vera Therapeutics operates in the biotechnology and health technology sectors, where its work targets conditions driven by abnormal immune activity and unmet medical needs. Headquartered in Brisbane, California, the company’s business today is centered on advancing immunology-focused drug candidates through clinical development and toward commercialization.

CEO Dr. Marshall W. Fordyce M.D. · 362 employees · United States · https://veratx.com